CELLTRION HEALTHCARE CO., LTD. This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn's disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| +56.72% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
